Shares of Viatris Inc. VTRS rose 1.89% to $10.80 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.04% to 6,115.07 and the ...

Viatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan and Upjohn (a division of Pfizer) in ...

Shares of Viatris Inc. VTRS slipped 1.03% to $10.62 Monday, on what proved to be an all-around positive trading session for ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday ...

David Einhorn's Greenlight Capital opened new positions in Centene (CNC), with about 871K shares, and Acadia Healthcare Company (ACHC), with 129K shares, during Q4 2024, the hedge fund disclosed in a ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other high-yield dividend stocks. Dividend stocks have been investors’ favorites for a long ...

One company value investors might notice is Viatris (VTRS). VTRS is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. Value investors also love the P/S ratio, which is ...

Check the time stamp on this data. Updated AI-Generated Signals for Viatris Inc. (VTRS) available here: VTRS. Type a few ...